BAX STOCK NOTICE: Baxter International Inc. Investors with Losses may have been Affected by Fraud – Contact BFA Law before December 15 Lawsuit Deadline GlobeNewswire October 22, 2025 NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against […]
(TSX:APLI),(Pinksheets:APLIF),(PinkSheets:APLIF), HALIFAX, Nova Scotia, Oct. 22, 2025 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTC Pink: APLIF) (“Appili” or the “Company”) today announced that it will attend the Biomedical Advanced Research and Development Authority (BARDA) Innovation Symposium on November 20, 2025, in Washington, D.C. The event brings together leaders from government, industry, and academia
(NasdaqGM:NRIX), SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the pricing of its underwritten registered offering of 24,485,799 shares of its common stock at a price of
Appili Therapeutics to Attend BARDA Innovation Symposium 2025 Highlights Government-Funded Pipeline and Expanding Role of Public-Private Partnerships in Biodefense Innovation GlobeNewswire October 22, 2025 HALIFAX, Nova Scotia, Oct. 22, 2025 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTC Pink: APLIF) (“Appili” or the “Company”) today announced that it will attend the Biomedical Advanced Research
Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock GlobeNewswire October 22, 2025 SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the pricing of its underwritten
NEW YORK, NY / ACCESS Newswire / October 22, 2025 / If you suffered a loss on your aTyr Pharma, Inc. (NASDAQ:ATYR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/atyr-pharma-inc-lawsuit-submission-form?prid=173390&wire=1&utm_campaign=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
NEW YORK, NY / ACCESS Newswire / October 22, 2025 / If you suffered a loss on your Cytokinetics, Incorporated (NASDAQ:CYTK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cytokinetics-incorporated-lawsuit-submission-form-2?prid=173392&wire=1&utm_campaign=24 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call
NEW YORK, NY / ACCESS Newswire / October 22, 2025 / If you suffered a loss on your WPP plc (NYSE:WPP) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/wpp-plc-lawsuit-submission-form?prid=173391&wire=1&utm_campaign=9 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call
(NASDAQ:GILT),(TASE:GILT.TA), PETAH TIKVA, Israel, Oct. 22, 2025 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today announced that it will release its third quarter 2025 financial results on Wednesday, November 12, 2025. Conference Call and WebcastFollowing the release, Adi Sfadia, Chief Executive
Gilat to Report Third Quarter 2025 Results on Wednesday, November 12th GlobeNewswire October 22, 2025 PETAH TIKVA, Israel, Oct. 22, 2025 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today announced that it will release its third quarter 2025 financial results on